How to buy Phio Pharmaceuticals stock (PHIO)

Phio Pharmaceuticals is a biotechnology business based in the US. Phio Pharmaceuticals shares (PHIO) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.76 – a decrease of 37.37% over the previous week. Phio Pharmaceuticals employs 8 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Phio Pharmaceuticals stock

Buy Phio Pharmaceuticals stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Phio Pharmaceuticals stock price (NASDAQ: PHIO)

Use our graph to track the performance of PHIO stocks over time.

Phio Pharmaceuticals shares at a glance

• Key figures

Information last updated 2024-12-15.

Latest market close	$1.76
52-week range	$2.17 - $10.35
50-day moving average more info button	$3.07
200-day moving average more info button	$5.19
Wall St. target price	$36.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-14.81

Is it a good time to buy Phio Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Phio Pharmaceuticals price performance over time

Historical closes compared with the close of $1.76 from 2024-12-20

1 week (2024-12-16)	-38.03%
1 month (2024-11-22)	-28.74%
3 months (2024-09-23)	-48.69%
6 months (2024-06-21)	156.93%

1 year (2023-12-22)	134.04%
2 years (2022-12-23)	-95.45%
3 years (2021-12-23)	127.44
5 years (2019-12-23)	885.0594

Phio Pharmaceuticals financials

Gross profit TTM	$-7,012,000
Return on assets TTM	-61.07%
Return on equity TTM	-126.86%
Profit margin	0%
Book value	$7.40
Market Capitalization more info button	$2 million

TTM: trailing 12 months

Phio Pharmaceuticals share dividends

We're not expecting Phio Pharmaceuticals to pay a dividend over the next 12 months.

Have Phio Pharmaceuticals's shares ever split?

Phio Pharmaceuticals's shares were split on a 1:9 basis on 4 July 2024 . So if you had owned 9 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Phio Pharmaceuticals shares – just the quantity. However, indirectly, the new 800% higher share price could have impacted the market appetite for Phio Pharmaceuticals shares which in turn could have impacted Phio Pharmaceuticals's share price.

Phio Pharmaceuticals share price volatility

Over the last 12 months, Phio Pharmaceuticals's shares have ranged in value from as little as $2.1678 up to $10.35. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Phio Pharmaceuticals's is 1.465. This would suggest that Phio Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Phio Pharmaceuticals overview

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp.

Frequently asked questions

What percentage of Phio Pharmaceuticals is owned by insiders or institutions?
Currently 5.894% of Phio Pharmaceuticals shares are held by insiders and 2.074% by institutions. How many people work for Phio Pharmaceuticals?
Latest data suggests 8 work at Phio Pharmaceuticals. When does the fiscal year end for Phio Pharmaceuticals?
Phio Pharmaceuticals's fiscal year ends in December. Where is Phio Pharmaceuticals based?
Phio Pharmaceuticals's address is: 11 Apex Drive, Marlborough, MA, United States, 01752 What is Phio Pharmaceuticals's ISIN number?
Phio Pharmaceuticals's international securities identification number is: US71880W3034 What is Phio Pharmaceuticals's CUSIP number?
Phio Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 74979C105